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Background: We evaluated the ability of quercetin, a natural antioxidant formulated in a 
specific delivery system, to reduce skin inflammation induced by a variety of stimuli, includ-
ing UV radiation, stimulation with a histamine solution, or contact with chemical irritants. In 
particular, we tested the soothing and anti-itch effect of Quercevita®, 1% cream for external 
use, a formulation characterized by a phospholipids-based delivery system.
Patients and methods: The study was a monocentric, single blind trial that enrolled a group 
of 30 healthy volunteers. The back of each subject was examined to identify four quadrants with 
no previous skin damage or naevi that were treated in order to induce a controlled and revers-
ible form of skin stress. The areas were treated as follows: no product; Quercevita® 1% cream, 
2 mg/cm2; placebo; positive control (a commercially available topical formulation containing 
1% dexchlorpheniramine).
Results: Only quercetin phospholipids 1% and dexchlorpheniramine 1% achieved a significant 
reduction in erythema with comparable results: (–10.05% [P=0.00329] for quercetin phospho-
lipids 1% vs –14.05% [P=0.00046] for the positive control). Moreover, quercetin phospholipids 
1% and dexchlorpheniramine 1% were both associated with a significant decrease in mean wheal 
diameter: (–13.25% and –12.23% for dexchlorpheniramine 1%, respectively). Similar findings 
were reported for the other tested parameters.
Conclusion: Quercetin has a skin protective effect against damage caused by a variety of 
insults, including UV radiation, histamine, or contact with toxic chemical compounds. Indeed, 
quercetin is able to reduce redness, itching, and inflammation of damaged skin; it may also help 
restore skin barrier function, increasing hydration, and reducing water loss.
Keywords: quercetin, anti-oxidant effect, anti-inflammation, reactive oxygen species
Introduction
The skin is subjected to continuous insults from environmental factors, external trauma, 
or pathological conditions.1 The production of reactive oxygen species (ROS), which 
results from exposure to UV radiation or contact with various toxic chemicals, is one 
of the main causes of skin damage and may contribute to the development of skin 
inflammation disorders, skin cancer, and cutaneous photoaging.2,3
Although the skin presents different mechanisms to protect itself from damage 
caused by ROS, the capacity of the system is limited and cannot cope with excessive 
exposure to oxidative damage. The use of topically applied antioxidants has been 
proposed to support the cutaneous antioxidant defense systems, thanks to their abil-
ity to quench free radicals and stop the inflammation process.3–6 Among the various 
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for their remarkable anti-oxidant, anti-inflammatory, 
chemo-protective, and chemo-therapeutic effects.7–9
Quercetin is one of the most abundant natural flavonoids, 
commonly found in fruits and vegetables.10 It shows supe-
rior anti-oxidant activity within the flavonoids family11 and 
it acts mainly by scavenging oxygen radicals,12 protecting 
lipids against peroxidation, and chelating metal ions.13 In 
addition, it displays anti-inflammatory properties, includ-
ing inhibition of cytokine production such as TNF-α14 and 
IL-8.15 The results of some animal studies have also reported 
its anti-nociceptive (pain-relieving) effects that might help 
reduce inflammatory-related pain.11,16
Despite the promising beneficial properties attributed 
to quercetin, it is important to underline that most of the 
information is derived from in vitro or in vivo animal studies, 
while the experience of the skin protective effect of quercetin 
in human subjects is still limited.
One of the main limits to the use of quercetin as skin 
protecting agent is its poor water solubility and low skin 
permeability;17 in fact, suitable percutaneous absorption is 
considered an essential requirement for topical protective 
agents. Many researchers have focused on the development 
of new strategies to increase quercetin skin permeability, 
including the use of prodrugs, liposomes, and novel vesicular 
systems.18–20
In this study we evaluated the ability of quercetin 
(formulated in a specific delivery system) to reduce skin 
inflammation induced by a variety of stimuli, including UV 
radiation, stimulation with a histamine solution, or contact 
with chemical barrier distributors such as sodium lauryl 
sulfate (SLS) or glycolic acid (GA).
In particular we tested the soothing and anti-itch effect 
of Quercevita®, 1% cream for external use, a formulation 
characterized by a phospholipids-based delivery system used 
to increase the ability of quercetin to permeate the skin.
Patients and methods
Study design
This study was conducted in line with the Declaration of 
Helsinki and was approved by the independent ethics com-
mittee ALLTOX IEC (ref 661-001-00260115).
The study was a monocentric, single blind trial that 
enrolled a group of 30 healthy volunteers. The back of each 
subject was examined to identify four quadrants with no 
previous skin damage or naevi that were treated in order to 
induce a controlled and reversible form of skin stress. Each 
identified quadrant was divided into four areas and treated 
as follows:
•	 Quadrant 1: exposure to a fixed dose of UVA + UVB 
radiations emitted by a solar simulator, equal to 150% 
of the minimal erythema-inducing dose; the dose was 
calculated on the basis of subject’s specific phototype.
•	 Quadrant 2: prick test with histamine. This procedure was 
performed on the back and also on the volar surface of 
the forearm of each volunteer in order to obtain a more 
precise itch rating.
•	 Quadrant 3: application of four patches containing 
0.07–0.1 mL of SLS solution 1%; each patch was left in 
contact with the skin for 24 hours.
•	 Quadrant 4: application of four patches containing 
0.07–0.1 mL of GA solution 1%; each patch was left in 
contact with the skin for 24 hours.
The four identified areas of each quadrant were than 
treated with the following products, applied by specialized 
personnel in non-occlusive cutaneous applications:
•	 Negative control: no product.
•	 Active treatment: Quercevita® 1% cream, 2 mg/cm2; 
sunflower phospholipids-based delivery system of quer-
cetin, according to the Phytosome® technology. The exact 
composition is reported in Table 1.
•	 Placebo: placebo formulation (same composition as 
the tested formulation but devoid of the 1% quercetin, 
replaced by water), 2 mg/cm2.
•	 Positive control: a commercially available topical formu-
lation containing 1% dexchlorpheniramine (Polaramin®, 
MSD, Rome, Italy) 2 mg/cm2.
The following parameters were assessed after the induc-
tion of skin inflammation (T0) and following the application 
of the products, at defined time-points:
•	 Quadrant 1: erythema (E), measured with the Mexameter® 
index at T0 (24 hours after irradiation) and T4 (4 hours 
after treatment application).






Polyacrylamide, C13-14 Isoparaffin, Laureth 7 3.00
Hydrogenated polydecene 8.50
Caprylic/capric triglycerides 2.00
lecithin (synonym: phosphatidylcholine), quercetin 1.00
lecithin, tocopherol, ascorbyl palmitate, citric acid 0.10
phenoxyethanol 0.60
Imidazolidinyl urea 0.30
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Soothing and anti-itch effect of quercetin
•	 Quadrant 2: wheal diameter (mm) and subjective evalua-
tion of itching sensation measured with the visual analog 
scale (VAS; from 0= no itch to 10= maximum itch) at T0 
(10 minutes after prick test), T10m, and T30m (10 and 
30 minutes after treatment application).
•	 Quadrant 3 and 4: E and hydration value at T0 (15 min-
utes after removal of the patches), T2, and T4 (2 and 
4 hours after treatment application); trans-epidermal 
water loss (TEWL) at T0 (15 minutes after removal of 
the patches), T4, and T24 (4 and 24 hours after treatments 
application).
An empty patch was applied on the back of each volunteer 
and left in contact with the skin for 24 hours as a negative 
control for erythema. In this area E was measured 15 minutes 
after patch removal.
population
The healthy volunteers included in the study were identified 
from the database of volunteers of the Abich Test Center 
and were adult (from 18 to 65 years old) male or female 
subjects. All the participants were able to understand the 
characteristics of the study, the requested observation times, 
the tasks implied, and the possible risks, and they all signed 
an informed consent form before the enrollment.
The following exclusion criteria were applied:
•	 pregnancy or nursing condition;
•	 blemishes, marks, including tattoos, scars, sunburn on 
the test site(s), or any skin lesions which might interfere 
with the test evaluation;
•	 medication (local and/or systemic) which might interfere 
with the test evaluation;
•	 participation in other simultaneous studies that might 
interfere with the test evaluation or participation in a 
previous one;
•	 allergy to histamine.
Statistical analysis
Continuous variables were analyzed by descriptive statistics. 
The Student’s t-test analysis was performed to evaluate the 
significance of the differences measured between different 




UV irradiation resulted in a similar development of erythema 
in the four treated areas. The average E values measured 
before (T0) and after (T4) treatment application are reported 
in Table 2, together with the percentage variations between the 
two time-points. Overall, only quercetin phospholipids 1% 
and dexchlorpheniramine 1% achieved a significant reduction 
in erythema with comparable results: –10.05% (P=0.00329) 
for quercetin phospholipids 1% vs –14.05% (P=0.00046) for 
the positive control. Both placebo and no treatment resulted 
in a non-significant decrease in erythema (Table 2).
Histamine prick test
After the histamine prick test the mean wheal diameter was 
similar in the four affected areas. None of the products were 
able to reduce the mean wheal diameter 10 minutes after the 
application. However, after 20 additional minutes, quercetin 
phospholipids 1% and dexchlorpheniramine 1% were both 
associated with a significant decrease in mean wheal diame-
ter: -13.25% for quercetin phospholipids 1% (from 4.2 to 
3.6 mm; P=0.00019) and -12.23% for dexchlorpheniramine 
1% (from 4.0 to 3.5; P=0.00257). At T30, the mean wheal 
diameter was also slightly reduced with no treatment or when 
the placebo formulation was applied; however this reduc-
tion was extremely limited and not statistically significant 
(Figure 1).
According to the results of the VAS test, subjects expe-
rienced a reduction in itching with all the treatments; the 
decrease in the itching sensation started 10 minutes after the 
application of the products, and further decreased at T30m. 
Although the changes in the VAS score were statistically 
significant for all the four treatments considered – both com-
paring T10m vs T0 or T30m vs T10m – it must be noted that 
after 10 minutes quercetin phospholipids 1% and dexchlo-
rpheniramine 1% achieved a higher reduction in VAS score 
compared to placebo or no treatment (Figure 2).
SlS solution
The erythema values measured after the application of SLS 
patches and after 2 and 4 hours’ skin treatment are reported 
in Table 3. Overall, only quercetin phospholipids 1% and dex-
chlorpheniramine 1% were able to reduce erythema, while no 
Table 2 Mean ± standard error erythema (e) values after UV 
irradiation (T0) and 4 hours (T4) after treatment application
Treatment E value T0 E value T4 % Variations  
T0 vs T4
P-value
no treatment 313±15 310±14 0.68% 0.389
Quercetin  
phospholipids 1%
311±14 273±14 -10.05% 0.003
placebo 306±14 297±13 -1.75% 0.130
Dexchlorpheniramine  
1%











































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1






















Figure 1 Mean wheal diameter after histamine prick test (T0) and 10 (T10) and 30 (T30) minutes after treatment application.


























Figure 2 Mean itching values after histamine prick test (T0) and 10 (T10) and 30 (T30) minutes after treatment application.
Notes: Bars represent standard deviation. C– is the non-treated (or control area). C+ is the positive control area.
significant effect was reported for placebo and no treatment. 
The reduction in E values was already visible 2 hours after 
quercetin phospholipids 1% (–7.30%; P=0.00027) and dex-
chlorpheniramine 1% (–9.50%; P=0.00397) application and 
was even more visible after 4 hours: –17.01% (P,0.0001) 
for quercetin phospholipids 1% and –18.39% (P,0.0001) 
for dexchlorpheniramine 1% (Table 3).
The hydration values were increased both after 2 and 4 
hours in the areas treated with quercetin phospholipids 1% 
and dexchlorpheniramine 1%. Interestingly, after 2 hours 
of treatment only quercetin phospholipids 1% was able to 
induce a significant increase in hydration (12.85%; P=0.025). 
A positive trend was observed for dexchlorpheniramine 1% 
(10.73%), but the difference was not statistically signifi-
cant (P=0.29761). Both treatments reported a statistically 
 significant increase in hydration at T4: 24.03% (P,0.0001) 
for quercetin phospholipids 1%, and 19.23% (P=0.04702) 
for dexchlorpheniramine 1%. While placebo had no effect 
on the hydration level, the absence of treatment resulted in 
a slight but statistically significant decrease in hydration at 
T4 (-3.16%, P=0.04705).
The mean TEWL values were significantly decreased in 
areas treated with quercetin phospholipids 1% and dexchlor-
pheniramine 1% both after 4 and 24 hours’ treatment. At 
T4 the mean decrease in TEWL was –24.94% (P=0.00015) 
for quercetin phospholipids 1% and –24.00% (P=0.00069) 
for dexchlorpheniramine 1%; after 24 hours the registered 
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Soothing and anti-itch effect of quercetin
for the two treatments, respectively. Of note, the absence of 
treatment also resulted in a significant decrease in TEWL 
values, although the reduction was considerably less than 
that obtained with the active treatment or the positive control 
(–11.01%, P=0.02046). No remarkable difference was 
observed with placebo.
Ga solution
The results observed after treatment with GA were similar 
to those reported with the SLS solution. Only quercetin 
phospholipids 1% and dexchlorpheniramine 1% resulted in 
a significant decrease in E values both after 2 hours (–8.20%, 
P=0.00064 and –8.68%, P,0.0001, respectively) and 4 hours 
(–16.83%, P,0.0001 and –17.80%, P,0.0001, respectively). 
No statistically significant difference was reported with pla-
cebo or no treatment (Table 4).
A positive trend toward the increase in hydration was 
measured at T2 and T4 with quercetin phospholipids 1% and 
dexchlorpheniramine 1%: 8.30% and 16.48% with quercetin 
phospholipids 1%, and 6.29% and 9.29% with dexchlorphe-
niramine 1%, at the two time-points, respectively. However, 
the increase was statistically significant only after 4 hours of 
quercetin phospholipids 1% treatment: 16.48% (P=0.00863). 
Both placebo and no treatment resulted in a continuous but 
not statistically significant reduction in hydration.
TEWL was significantly decreased after 4 and 24 hours 
in areas treated with quercetin phospholipids 1% and dex-
chlorpheniramine 1%. The percentage variation measured at 
T4 was –32.15% (P=0.00007) for quercetin phospholipids 
1% and –35.37% (P=0.00028) for dexchlorpheniramine 1%, 
while after 24 hours the reduction was equal to –45.69% 
(P,0.0001) and –54.28% (P=0.00001), respectively, 
compared to T0. No significant changes were observed in 
areas treated with placebo, while the absence of treatment 
resulted in a statistically significant reduction in TEWL after 
24 hours; however, the results were remarkably lower than 
those observed with active treatment or positive control 
(-6.48; P=0.03707).
Discussion
The results of our study suggest that quercetin phospholipids 
1%, cream for external use, has a significant soothing effect 
against skin inflammation induced by different insults, 
including UV radiation, histamine prick test, skin barrier 
disruption induced by contact with SLS or GA solutions. The 
soothing effect is visible as a reduction in redness (erythema), 
wheal diameter, and itching sensation. In addition, our results 
suggest the ability of this formulation to help restore the 
skin barrier functions, given the increase in hydration and 
the reduction in TEWL. The separate effect of the different 
components – quercetin, phospholipids, and well-known 
antioxidants such as ascorbic acid and tocopherol – was not 
evaluated in this study, since they are synergic in constituting 
a single active entity.
The reduction in erythema obtained with quercetin 
phospholipids 1% was similar to that observed after anti-
histaminic treatment (dexchlorpheniramine 1%), used as 
positive control. Indeed, 4 hours after the application, both 
treatments were able to achieve a significant reduction in 
skin redness with comparable values, regardless of the type 
Table 3 Mean ± standard error erythema values after application of SlS patches (T0) and 2 (T2) and 4 (T4) hours after treatment 
application
Treatment T0 T2 T4 % Variations T2 vs T0  
(P-value)
% Variations T4 vs T0 
(P-value)
no treatment 330±17 341±15 334±15 5.76% (P=0.11808) 4.74% (P=0.38525)
Quercetin phospholipids 1% 351±18 321±16 287±15 -7.30% (P=0.00027) -17.01% (P,0.0001)
placebo 321±17 331±18 319±16 4.87% (P=0.13174) 1.43% (P=0.41323)
Dexchlorpheniramine 1% 340±16 307±19 274±17 -9.50% (P=0.00397) -18.39% (P,0.0001)
Abbreviation: SlS, sodium lauryl sulfate.
Table 4 Mean ± standard error erythema values after application of Ga patches (T0) and 2 (T2) and 4 (T4) hours after treatment 
application
Treatment T0 T2 T4 % Variations T2 vs T0  
(P-value)
% Variations T4 vs T0 
(P-value)
no treatment 321±17 326±16 322±15 3.52% (P=0.11808) 2.90% (P=0.46091)
Quercetin phospholipids 1% 362±17 328±14 296±14 –8.20% (P=0.00064) –16.83% (P,0.0001)
placebo 345±19 354±18 346±17 5.70% (P=0.21274) 3.23% (P=0.45389)
Dexchlorpheniramine 1% 359±12 327±12 295±14 –8.68% (P,0.0001) –17.80% (P,0.0001)
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of agent used as skin irritant. Of note, the highest reduction 
in erythema was achieved for both treatments after skin 
 exposure to GA, while the lowest effect was registered after 
UV radiation. The percentage variations in erythema reported 
for quercetin phospholipids 1% and dexchlorpheniramine 
1%, respectively, were: -10.05% and -14.05% after exposure 
to UV radiation, -17.01% and -18.39% after contact with 
SLS solution, and -16.83% and -17.80% after contact with 
GA solution.
The photoprotective properties of quercetin have been 
investigated in a number of studies.21,22 Erden Inal et al21 exam-
ined the effect of quercetin on UVA radiation on the skin in 
an in vivo animal study. They observed that exposure to UVA 
radiation resulted in oxidative damage to the skin, measured as 
an increase in the levels of malondialdehyde – an end-product 
of lipid peroxidation – and a significant decrease in antioxidant 
enzymes such as glutathione peroxidase, glutathione reductase, 
catalase, and superoxide dismutase. In rats treated with quer-
cetin, malondialdehyde levels were significantly decreased if 
compared to rats that received UVA radiation alone, and the 
reduction in antioxidant enzymes was considerably lower. The 
authors concluded that treatment with quercetin might have a 
beneficial effect on skin cells, by protecting them or reducing 
the harmful effects of UVA irradiation.
In another study, conducted by Vicentini et al on the skin 
of hairless mice, quercetin significantly reduced skin dam-
age caused by UVB radiation. The authors observed that 
daily application of a water/oil microemulsion of quercetin 
prevented the UVB irradiation-induced depletion of glutathi-
one, one of the most important endogenous mechanisms for 
protection against UV-induced ROS. In addition, quercetin 
was able to reduce the secretion/activation of MMPs. These 
proteinases, whose levels are increased after UV radiation, 
act by degrading skin collagen and elastin, thus contributing 
to skin photoaging.22
The results of our study further confirm those previously 
reported on the anti-oxidant properties of quercetin and on its 
ability to reduce the oxidative damage caused by UV radia-
tion. However, to our knowledge, this is the first time that 
the effect of quercetin on the prevention of UV-induced skin 
damage has been demonstrated in human subjects.
In our study we also observed that quercetin phospholipids 
1% was able to reduce skin irritation caused by chemical 
agents such as SLS. These results are in contrast with those 
previously reported by Katsarou et al.23 The authors evaluated 
the effect of quercetin on acute skin irritation induced by 
SLS 2% solution in 15 patients with contact dermatitis. The 
results of the study showed that acute inflammation induced 
by SLS did not significantly improve after treatment with 
quercetin 7.5% and that erythema and TEWL indexes, after 
a consistent initial increase, were only slightly reduced after 
5 days of quercetin treatment and did not return to baseline 
levels even after 7 days of therapy.23
Conversely, we reported not only a reduction in erythema, 
but also an improvement in the skin barrier functions, as 
revealed by the increase in hydration and the decrease in 
TEWL. Our results suggest that the anti-oxidant activity of 
quercetin, and in particular the reduction in lipid peroxida-
tion, may have a crucial effect in the restoration of the bar-
rier function of damaged skin. Indeed, lipids in the stratum 
corneum play an important role for the maintenance of 
the permeability barrier of the skin, and lipid peroxidation 
products are known for their toxic effect on mammalian 
skin cells.24
The differences observed between our and Katsarou 
et al’s study may lay in the different concentrations of the 
agents used (SLS 1% vs 2%) or in the fact that, although the 
concentration of quercetin used by Katsarou et al was higher 
than that utilized in our study, the lack of an appropriate 
delivery system might have hampered the skin permeability 
of the molecule. Moreover, the different experimental and 
evaluation protocols followed have largely contributed to the 
observed discrepancy between our results and theirs.
The results observed after contact with GA solution are 
similar to those reported for SLS. To our knowledge no pre-
vious studies have investigated the activity of quercetin on 
skin irritation induced by this chemical agent.
Lastly, in our study quercetin phospholipids 1% displayed 
anti-histaminic properties, with a reduction in mean wheal 
diameter and itching after histamine prick test comparable to 
that achieved by the positive control (dexchlorpheniramine 
maleate). The anti-allergic effect of quercetin has been 
suggested by a number of in vitro and animal studies that 
showed its inhibitory action on the secretory response of 
activated mast cells25,26 and on the release of histamine from 
basophils.27,28
Of note, we conducted a separate in vitro study to assess 
the activity of Quercevita® in inhibiting basophil degranu-
lation in rodent cells. Degranulation was stimulated with 
a cross-linking of the IgE human receptor (FcRI) with a 
specific polyclonal antibody and was assessed by measuring 
the release of β-hexosaminidase – a mediator secreted after 
basophils’ activation. The inhibitory activity of Quercevita® 
was compared to that obtained with hyaluronic acid (posi-
tive control). Quercevita® resulted in an effective and dose-
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Soothing and anti-itch effect of quercetin
of 83.6% (at 10 µg/mL), compared to 79.2% obtained with 
the positive control.29
These results suggest that quercetin exerts a dual anti-allergy 
action: on one hand it inhibits the release of histamine from 
basophil cells; on the other, if histamine is present, it reduces 
skin redness and itching caused by histamine. These activities, 
combined with the anti-inflammatory action exerted by quercetin 
and the inhibition of cytokine production, might account for the 
reduction in skin irritation observed in our study. These results 
prompt future study to investigate the skin protective effect of 
quercetin on skin damage related to allergic reactions. In addi-
tion, it would be useful to explore other potential delivery meth-
ods (eg, nanoparticles, pending a proper and careful assessment 
of their safety in line with European Union requirements).
Conclusion
Overall the results of our study suggest that Quercevita® 
1% has a skin protective effect against damage caused by 
a variety of insults, including UV radiation, histamine, or 
contact with toxic chemical compounds. Indeed, this formu-
lation is able to reduce redness, itching, and inflammation 
of damaged skin; in addition it may help restore skin barrier 
function, increasing hydration, and reducing water loss. These 
effects are achieved mainly due to the anti-oxidant and anti-
inflammatory properties of quercetin, enabling it to scavenge 
free radicals and reduce the oxidative damage caused by UV 
radiation, decrease lipid peroxidation, and inhibit the produc-
tion of inflammatory enzymes and other cytokines.
Moreover, quercetin exhibits anti-allergic properties, as it 
reduces irritation and itching caused by histamine prick test. 
This activity adds to the inhibitory effect exerted by quercetin on 
basophil degranulation and consequential histamine release.
To our knowledge, this is the first study where the multiple 
properties of quercetin on skin soothing and protection have 
been reported in human subjects.
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